Pharmaceuticals, Biotechnology and Life Sciences
Final analysis of Janssen’s Phase 3 SPARTAN study presented during ASCO Virtual Scientific Programme suggests 14-month improvement in median overall…
CHICAGO–(BUSINESS WIRE)–Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize…
Longer-term follow-up data from Phase 1b/2 CARTITUDE-1 study demonstrate 100 percent overall response rate, 86 percent stringent complete response rate…
2020 American Society of Gene & Cell Therapy Annual (ASGCT) virtual Meeting European Forum for Good Clinical Practice (EFGCP) Webinar…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new…
NUBEQA reduced the risk of death by 31 percent (HR=0.69, 95% CI 0.53-0.88; p=0.003) compared to placebo in its secondary…
Research data from the pivotal phase 2 DESTINY-Gastric01 trial of ENHERTU® to be presented along with phase 2 DESTINY-Lung01 and…
PEN-866 demonstrates a favorable therapeutic index with a broad therapeutic range, was well tolerated and showed evidence of anti-tumor activity…
Data from Pivotal Phase 3 Trial Showed KEYTRUDA Plus Chemotherapy Reduced the Risk of Disease Progression or Death by 35%…
– Data from three cohorts of phase 1b COSMIC-021 trial to be presented during the 2020 American Society of Clinical…